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Conclusions: Performing patient-specific QA for VMAT plan by using 
MapCHECK with IMF tool shows the result of agreement between 
Eclipse plan and measurement comparable with using ArcCHECK 3D 
diode array.  
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Purpose/Objective: The purpose of this work is to determine the 
statistical correlation between 2D IMRT QA passing rates and several 
clinically relevant, anatomy-based dose errors for per patient IMRTQA. 
Materials and Methods: Thirty patients which performed QA of the 
treatment plan of the VMAT(VARIAN MedicalSystems, USA) with 
prostate cancer in the past were examined. Each planned with 10 MV 
linear accelerators (Novalis-Tx; Brain LAB) using a commercial 
treatment planning system (ECLIPSE; VARIAN Medical Systems, USA) 
and VMAT. In this study was compared with 2D or volume gamma pass 
rate and Dose Volume Histogram (DVH), and absolute dose. 2D gamma 
pass rate analysis was measured by 2D pixel ion-chamber (MatriXX; 
IBA, Germany). Volume gamma pass rate and DVH were computed by 
COMPASS MatriXX systems(IBA, Germany). The dose response data 
measured by the MatriXX(IBA, Germany) was imported to the COMPASS 
MatriXX systems, and volume gamma and DVH were calculated. The 
COMPASS MatriXX systems can perform only dose calculation by using 
imported DICOM plan data and dose response. As for the absorbed 
dose was compared with 0.6ml Farmer type ion-chamber and 
COMPASS MatriXX systems. An absorbed dose was compared with mean 
dose of the same area volume as the area volume measured by ion-
chamber of the IMRT phantom, and correlation was investigated. 
Results: A variation of 2D gamma pass rate was larger than volume 
gamma. As a result of performing comparison of 2D gamma pass rate 
and DVH, absorbed dose error was less than 5% in DVH when 2D 
gamma pass rate was more than 95% of PTV. However,even if the 
rectum and bladder were more than 95% gamma pass rate, there was 
dose error more than 5% in 40% of all measured data. There were 
correlated with absolute dose measured by 0.6ml ion-chamber and 
computed by the COMPASS MatriXX systems (p<0.01).  
Conclusions: Although IMRT Plan QA by means of 2D or volume gamma 
pass rate were suitable as objective rating of distribution, it was 
suggested that these were not suitable as clinical assessment of IMRT 
Plan.  
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Purpose/Objective: The introduction of VMAT in clinical routine can 
be limited for the complexity and time needed in pre-treatment 
verification, decreasing the number of patients that could benefit. A 
fast and reliable dosimetric device is then required. Since 2009, over 
400 patients have been treated with Volumetric modulated arc 
therapy (VMAT) at Fondazione di Ricerca e Cura 'Giovanni Paolo II' of 
Campobasso, Italy. In this study we present the three-years results of 
our patient specific QA program using the PTW seven29/Octavius 
system and our institutional guidelines for VMAT delivery.  
Materials and Methods: From June 2009 to October 2012, 410 
patients were treated with VMAT technique at our institution using 
Elekta linacs and Oncentra Masterplan TPS. Patients were divided in 
three groups: (1) 125 patients with high-modulated complex 
treatments for head-neck, rectal, endometrial and brain tumours, all 
treated with Simultaneous Integrated Boost strategy using two arcs; 
(2) 140 patients with prostate and vaginal tumours and (3) 145 
patients undergone to radiosurgery or extracranial stereotactic 
techniques for bone, liver, lung, abdominal and pelvic metastasis, 
treated by one arc. The absolute doses were measured utilizing the 
PTW Seven29 ion-chamber array and the Octavius phantom. VMAT 
plans were recalculated on phantoms representing the Octavius 
geometry and density; for each arc the doses were measured both on 
coronal and sagittal planes, for a total of 1070 measurements. 
Agreement of measured and predicted doses were evaluated using 
gamma index set at 3%/3mm. Three scalar metrics were evaluated for 
each measurement: (a) percentage of points with gamma value less 
than one (Pγ<1), (b) mean gamma (γmean), and (c) maximum gamma 
(γmax). Dose measurements at isocenter point were extracted by the 
seven29 central 0.125 cc ion chamber. 
Results: Pγ<1, γmean and γmax averaged over all treatment sites were 
96.8% ± 3.0%, 0.37 ± 0.08 and 1.58 ± 0.70, respectively. For the 
patients in group (1), Pγ<1, γmean and γmax were 95.7% ± 3.0%, 0.39 ± 
0.08 and 1.90 ± 0.62, respectively. These values reached 98.2% ± 
3.3%, 0.35 ± 0.09 and 1.13 ± 0.61 values in group (2) and 98.3% ± 2.3%, 
0.31 ± 0.08 and 1.24 ± 0.70 values in group (3). Our local confidence 
limits for Pγ<1 were determined to be 9.1% over all treatment sites, 
and 10.2%, 8.1%, and 6.2%, for patients in group 1, 2 and 3, 
respectively. Mean values and SD of ion-chamber differences between 
isocenter measured and calculated doses were -0.4% ± 2.8%, -0.7% ± 
1.6% and 0.5% ± 2.0% for group 1, 2, and 3, respectively, supplying our 
local confidence limit of 5.9%, 3.8% and 4.4%.  
Conclusions: The PTW seven29/Octavius system allows a fast and 
accurate dosimetric procedure for VMAT pre-treatment verification, 
benefiting from all the advantages of ionization chamber absolute 
dosimetry. Despite the increased complexity in VMAT treatments, our 
local confidence limits were comparable to those of AAPM TG 119.  
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Purpose/Objective: In the field of radiotherapy (RT) vast resources 
are being used on quality assurance (QA) to ensure the most precise 
treatment delivery. One important parameter to control and monitor 
is the dosimetric output from the linear accelerator. In recent years 
at this institute, this has been done by weekly output measurements 
with an ion chamber in a Perspex phantom. These measurements have 
been supplemented by daily output measurements using LINACHECK 
from PTW. However, modern linear accelerators allows for such 
measurements using the onboard Electronic Portal Imaging Device 
(EPID). The purpose of this study has been to design, code and 
implement a software solution for measuring and evaluating the daily 
output on the Varian iX and Truebeam accelerators using the EPID. 
Materials and Methods: Daily warm-up and output measurement test 
patients were created for each accelerator. These consisted of four 
fields: two warm-up fields (25 x 25 cm2, 400 MU, 6 and 15 MV) and 
two output measurement fields (25 x 25 cm2, 100 MU, 6 and 15 MV) 
with the EPID positioned at SID = 100 cm and the measurements 
carried out by integrating dose over time. To collect reference data 
and allow for dosimetrically equivalent measurements, the output of 
all accelerators was measured and adjusted in water to within ± 0.3 % 
of reference values. Afterwards the integrated image mode of the 
EPID was calibrated for the clinical used D/R, followed by a dosimetric 
calibration using a 10x10 cm2 field and 100 MU. Reference data was 
then collected using the test patients. All data was exported from the 
TPS as DICOM files. An algorithm for sorting measurements, 
calculating output, beam quality, symmetry and plotting in- and cross-
line profiles was created using MATLAB. For easy accessibility and 
quick handling a graphical user interface (GUI) was also coded using 
the MATLAB GUI editor. Finally the algorithm and GUI were compiled 
to an executable, allowing the software to run independently of a 
MATLAB installation using the MATLAB Compiler Runtime (MCR). 
Several versions of the software was designed, compiled and deployed 
each targeting a specific personal group with different requirements. 
All measurements and results were saved to MATLAB data files for 
storage and easy accessibility. 
Results: A lot of energy was used in the design phase of this project 
which clearly paid out in implementation and evaluation phase, where 
only minor issues related to the software arose, being primarily coding 
errors related to e.g. saving data. As a result of this several new 
versions with error corrections or minor functionality tweaks were 
deployed over the first months of implementation. 
Conclusions: Using MATLAB for creating software to interact with data 
measured using the EPID exported via DICOM has proven itself 
possible, easy and reliable. Making in-house software gives the 
benefits of a highly customizable system alongside complete 
knowledge and control over algorithms and data handling. 
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Purpose/Objective: Verification of the calculated and delivered dose 
trough independent verification of treatment planning system (TPS) 
and in vivo dosimetry are important part of the overall radiotherapy 
quality assurance (QA). The verification of TPS was done according to 
IAEA recommendations and put an emphasis on dosimetry part of the 
treatment planning and delivery processes. In vivo dosimetry was 
implemented as quality assurance procedure for patient treatment 
verification. 
Materials and Methods: Verification of TPS was done with 
anthropomorphic phantom which was later also used for in vivo 
measurements prior to patient measurements. Set of clinical test 
cases suggested by the IAEA, covering a range of typical clinical 
radiation techniques found in 3D conformal radiotherapy treatment 
(3D CRT) was used both for TPS and in vivo dosimetry verification. The 
doses were measured with ion chamber and semiconductor diodes, 
and compared to doses calculated in TPS for interest points for test 
cases and points in build up for entrance in vivo readings. 
Consequently, set of breast patients were checked by in vivo during 
their regular treatments. For patient treatment verification, 
tangential half fields were used and in vivo diodes were placed off 
axis, under large gantry angles, with different wedge types and 
angles. 
Results: The measurements were conducted for 6 MV beam energy 
and advanced calculation algorithm. The differences between the 
measured and calculated doses for all test cases were within the 
tolerance level. The differences of in vivo phantom measurements and 
TPS calculation varied depending on the test type: 0.5% for open field 
case to 5.3% for enhanced dynamic wedge (EDW) test case. In vivo 
measurements conducted for breast patients showed difference of not 
more than 5% in comparison with values calculated by TPS.  
Conclusions: After verification of TPS calculation, dose calibration 
and correction factors for semiconductor diodes were checked and 
prediction for in vivo doses in TPS was verified. The errors of 5 % 
magnitude are common in clinics worldwide and clinical 
implementation of in vivo dosimetry in our clinic has given confidence 
that patients are being treated with prescribed dose. This was 
opportunity to systematically review the uncertainties involved in 
treatment planning and dose delivery processes leading to more 
accurate patient treatment. 
Acknowledgement: The work has been supported by IAEA through the 
national SRB6006 and regional RER 6023 technical cooperation 
project.  
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Purpose/Objective: We investigate how QA criteria relate to 
sensitivity end specificity for increased normal tissue toxicity risk and 
risk of decreased tumour control in rotational therapy for prostate 
cancer. 
Materials and Methods: QA analysis for 8 clinical plans and 160 plans 
with deliberately introduced errors was carried out using ten sets of 
QA criteria. The tumour control probability (TCP), and risk of rectal 
bleeding (NTCP_rectum), were calculated. An unacceptable plan was 
defined as a plan where TCP decreased by more than 2%, or the NTCP 
increased by more than 50%, as compared with the clinical plan. We 
chose the 50% NTCP threshold as the rectum was in the low dose 
region. The sensitivity and specificity for detecting unacceptable 
plans and their sum (S+S) were determined for each QA criteria set. 
The diagnostic quality of the QA criteria was also assessed by 
receiver-operator characteristics curves. For dose difference (DD) = 3 
% and distance to agreement (DTA) = 3 mm; the required percentage 
of gamma smaller than 1 for acceptance (A) was scanned and the 
value of A which maximised S+S was determined. In an iterative 
process TCP and TNCP respectively were varied to find the values 
which corresponded to DD=3%, DTA =3 mm and A = 95 %. 
Results: A set of DD = 3 %; DTA = 3 mm and A = 95 % corresponds to 
ensuring that TCP is > 99 %; and NTCP < 160%; of the clinical values. 
For DD = 3 %; DTA = 3 mm, S+S was maximised for A = 95 %. We could 
not identify a single set of QA parameters that was significantly better 
than the others. However, three of the criteria had a significantly 
lower area under the ROC curve than the best parameter sets.  
Conclusions: A method for relating clinical risk estimates to QA 
parameters has been demonstrated. This method can be used to 
determine A for given DD and DTA values once the relative weights of 
sensitivity and specificity have been chosen by the user. It can also be 
used to determine which values of ΔTCP and ΔNTCP correspond to the 
chosen QA criteria set.  
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Purpose/Objective: To assess the accuracy of a three-dimensional 
dose verification technique for patient-specific Quality Assurance (QA) 
in active scanning proton therapy. Critical cases of major deviations 
between treatment planning system (TPS) calculated and measured 
data points are further investigated with Monte Carlo (MC) 
simulations.  
Materials and Methods: Treatment plan verification is performed in a 
water phantom with the simultaneous use of twelve small-volume 
ionization chambers (one data set), aligned in four rows in a way that 
none of them perturbs the other ones. The acceptance threshold is set 
at 5% for both mean deviation between measured and calculated 
doses and one standard deviation, over twelve measurement points. 
Results of 180 data sets, obtained along one year of clinical activity at 
the Italian National Center for Oncological Hadron Therapy (CNAO), 
were analyzed.Data were organized based on tumor site (skull versus 
sacrum) and TPS optimization technique (single field uniform dose 
SFUD versus intensity modulated particle therapy IMPT). A warning 
level was defined for data sets showing more than 30% of single point 
absolute deviations higher than 5% and needing further investigation. 
A MC tool for plan verification in water was implemented to evaluate 
the impact of dose calculation, dose delivery and measurement set-up 
uncertainties on the nine cases resulting out of the warning level.  
Results: All patient-specific quality checks resulted within the 
acceptance threshold. Mean deviation between TPS dose calculation 
and measurement was less than ±3% in 86%of the cases. For targets 
located in the skull region an average higher deviation was found, 
compared to the sacrum region, due to more complex dose patterns 
involved. In addition, the use of a less robust optimization technique, 
such as IMPT compared to SFUD, produced much more scattered 
results and higher single point variation. When all sources of 
uncertainty were accounted for with the MC tool, all the simulated 
cases showed even higher level of agreement, with mean absolute 
deviation ≤ 2% (maximum absolute deviation< 5%). 
Conclusions: Along this first year of clinical activity, the results of all 
patient-specific QA checks performed using ICs in a 3D configuration 
were found within the acceptance threshold. The use of a MC-based 
tool to investigate potential causes of major deviations should be 
further explored, particularly for more complex IMPT plans. 
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Purpose/Objective: This study was performed to examine the effect 
of various factors on the optimization of volumetric modulated arc 
therapy (VMAT) patient specific quality assurance (QA). 
Materials and Methods: Plans were created in eclipse treatment 
planning system (TPS) and measurements were performed in Varian 
Clinac-iX linear accelerator. Fifteen VMAT Plans were compared on 
the basis of type of delivery, number of arcs, complexity (treatment 
site), number of target volumes, and inclusion/exclusion of couch in 
the plans. For the same cases seven field intensity modulated 
radiotherapy (IMRT) plans were also created to compare QA results. 
Planar dose measurements were performed using ImatriXX 2-D array 
system of IBA dosimetry. Percentage of pixels passed the 3%-3 mm 
gamma criterion (% dose difference and distance to agreement-DTA) 
was taken for the comparison. Point dose measurements were also 
performed and the percentage deviation of the calculated doses 
versus measured doses was compared. Student’st-test was performed 
for the statistical analysis of the QA results. 
Results: IMRT plans showed better QA results as compared to double-
arc plans for head & neck site with more than one target volume 
(99.6% vs. 97.91% for the mean percentage of pixels passing the set 
